RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Follow-Up Questions
Redhill Biopharma Ltd 'in CEO'su kimdir?
Mr. Dror Ben-Asher 2009 'den beri şirketle birlikte olan Redhill Biopharma Ltd 'in Chairman of the Board 'ıdır.
RDHL hissesinin fiyat performansı nasıl?
RDHL 'in mevcut fiyatı $1.68 'dir, son işlem günde 0.88% decreased etti.
Redhill Biopharma Ltd için ana iş temaları veya sektörler nelerdir?
Redhill Biopharma Ltd Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Redhill Biopharma Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
